tetano
Editor, Senior Moderator
Lyon, France - March 29, 2016 - Sanofi Pasteur, the vaccines division of Sanofi, announces published data on a vaccine strategy that elicited a broadly-reactive response against seasonal and pandemic H1N1 influenza viruses in mice. The article, entitled "Design and characterization of a computationally optimized broadly reactive hemagglutinin vaccine for H1N1 influenza viruses," appears in the current issue of the Journal of Virology. Sanofi Pasteur has an R&D collaboration agreement with the University of Georgia and representatives of both organizations will be presenting the data tomorrow, March 30, at the 2016 World Vaccine Congress being held in Washington, D.C.
Previously, a novel hemagglutinin (HA) for H5N1 influenza was derived using a methodology termed computationally optimized broadly reactive antigen (COBRA). This COBRA HA elicited a broad antibody response against H5N1 isolates from different clades in mice and nonhuman primates. In this new publication, the authors present pre-clinical efficacy data demonstrating that COBRA technology can be extended to elicit antibodies against many drifted H1 strains and has the potential to be used in the development of a "subtype universal" vaccine. According to the authors, "One of the challenges of developing next generation influenza A vaccines is the diversity of antigenically distinct isolates. We now report the characterization of a COBRA-based vaccine for both seasonal and pandemic H1N1 influenza isolates."
http://www.eurekalert.org/pub_releases/2016-03/sp-spu032816.php
Previously, a novel hemagglutinin (HA) for H5N1 influenza was derived using a methodology termed computationally optimized broadly reactive antigen (COBRA). This COBRA HA elicited a broad antibody response against H5N1 isolates from different clades in mice and nonhuman primates. In this new publication, the authors present pre-clinical efficacy data demonstrating that COBRA technology can be extended to elicit antibodies against many drifted H1 strains and has the potential to be used in the development of a "subtype universal" vaccine. According to the authors, "One of the challenges of developing next generation influenza A vaccines is the diversity of antigenically distinct isolates. We now report the characterization of a COBRA-based vaccine for both seasonal and pandemic H1N1 influenza isolates."
http://www.eurekalert.org/pub_releases/2016-03/sp-spu032816.php